MRES:
Institute of Biomedical Research unveils artificial intelligence
(AI) powered initiatives within its CBD product range, psilocybin
research, and cardiometabolic health solutions
CAPE TOWN, SOUTH AFRICA
-- June 7, 2023 -- InvestorsHub NewsWire -- Institute of
Biomedical Research Corp. (OTC
PINK: MRES)
("Institute of Biomedical Research" or the "Company"), a
nutraceutical biotechnology company focused on alternative
plant-based cannabinoids, medical psilocybin, and mental health
therapeutic research in addition to artificial
intelligence-powered, evidence-based sustainable nutritional
products and solutions is pleased to provide a comprehensive update
on their recent accomplishments and integration of artificial
intelligence (AI) in their biotechnology and medical
solutions.
Over the past 18 months,
the company along with its subsidiary M2Bio Sciences, has made
considerable advances towards its mission in developing exceptional
health products and solutions as well as further solidifying its
position as an innovator in the global biotech industry. Through
the application of cutting-edge AI algorithms and machine learning,
the company has created highly efficient nutritional assistance
solutions.
The company has also been
actively researching psychedelic compounds for potential
therapeutic use in mental health disorders. By employing AI-driven
techniques in data research and predictive models, leveraging AI
algorithms to analyze vast datasets and identify patterns, M2Bio
Sciences has made significant strides in understanding the
therapeutic potential and promising results in the treatment of
psychedelics for conditions such as depression, anxiety, and
post-traumatic stress disorder (PTSD).
M2Bio Sciences continues
to collaborate with leading experts and institutions to further
explore the therapeutic potential of psychedelic compounds. As one
of a handful of companies in the world, M2Bio Sciences is actively
researching the magic mushroom compound psilocybin by funding
research at the University of South Africa. The exploratory
research is aiming to discover novel indications for medical
conditions such as depression, inflammation, and substance
addiction.
"We are thrilled to
share the remarkable progress made by the Institute of Biomedical
Research.
Our
commitment to advancing biotechnology has fueled our success,
enabling us to develop ground-breaking solutions and contribute to
the betterment of global health. Integrating artificial
intelligence into biotechnology and medical solutions marks a
significant milestone for our company. By harnessing the power of
AI, we have unlocked new possibilities for improving global
healthcare outcomes and revolutionizing the way we approach medical
research and treatment." stated Jeff Robinson CEO of the
Institute of Biomedical Research.
The company also owns and
operates three medicinal cannabis consumer goods brands:
Medspresso™, Dr. AnnaRx™, and Liviana™. The brands span a wide
range of premium CBD- and mushroom-infused consumer goods including
bioceuticals, health and wellness, and precision foods and
beverages.
Recently, M2Enviro, the
sustainability division of M2Bio Sciences, announced it was gearing
up to introduce the world to Hempcelium. Hempcelium is a
sustainable, biodegradable, and eco-friendly packaging solution
made from a proprietary hemp and mycelium composite. Hempcelium is
an alternative to environmentally harmful polystyrene.
Looking forward, the
Institute of Biomedical Research and M2Bio Sciences remain
unwavering in their dedication to advancing biotechnology and
medical solutions through AI. Through ongoing research, innovation,
and strategic partnerships, they will continue to lead the industry
and improve the lives of millions.
About
Institute of Biomedical Research Corp./ DBA M2Bio
Sciences
Institute of Biomedical
Research Corp, is a nutraceutical biotechnology company focused on
alternative plant-based cannabinoids, psilocybin medical and mental
health therapeutic research, and artificial intelligence-powered,
evidence-based sustainable nutritional products and solutions that
develops and commercializes a range of CBD and mushrooms-based
products under Dr. AnnaRx™, Medspresso™, Liviana™ brands as well as
artificial intelligence-powered nutrition products and solutions
under the M2Biome brand. In addition, our research and clinical
trials with psilocybin are aimed at new therapies that will help
patients who suffer from alcohol addiction, mental illness, and
cardiovascular diseases. Our mission is to advance botanical-based
medicine to the forefront by deploying best-practice science and
medicine, clinical research, and emerging technologies such as
artificial intelligence. The Company is traded on the
Over-the-Counter Bulletin Board of NASDAQ under the trading symbol
"MRES".
Publicly traded Company
(OTC
Pink: MRES)
www.m2bio.co
jeff@m2bio.co
+27 72 333
2148
Find
M2Bio™ on social media
Facebook:
M2Bio
Instagram:
M2bio.Sciences
LinkedIn:
M2Bio
Twitter:
@M2bio
Find
Liviana™ on social media
Facebook:
Liviana.Health
Instagram:
@liviana.health
LinkedIn:
Liviana™ Health
Twitter:
@livianaoliveoil
Find
Medspresso™ on social media
Follow us on
Facebook:
Medspresso
Follow us on
Instagram:
@medspresso.official
Follow us on
LinkedIn:
Medspresso™ - More Than Just Coffee
Forward-Looking
Statements
Safe Harbour Statement -
In addition to historical information, this press release may
contain statements that constitute forward-looking statements
within the meaning of the Securities Act of 1933 and the Securities
Exchange Act of 1934, as amended by the Private Securities
Litigation Reform Act of 1995. Forward-looking statements contained
in this press release include the intent, belief, or expectations
of the Company and members of its management team with respect to
the Company's future business operations and the assumptions upon
which such statements are based. Prospective investors are
cautioned that any such forward-looking statements are not
guarantees of future performance, involve risks and uncertainties
and that actual results may differ materially from those
contemplated by such forward-looking statements. Factors that could
cause these differences to include, but are not limited to, failure
to complete anticipated sales under negotiations, lack of revenue
growth, client discontinuances, failure to realize improvements in
performance, efficiency, and profitability, and adverse
developments with respect to litigation or increased litigation
costs, the operation or performance of the Company's business units
or the market price of its common stock. Additional factors that
could cause actual results to differ materially from those
contemplated within this press release can also be found on the
Company's website. The Company disclaims any responsibility to
update any forward-looking statements.
Institute of Biomedical ... (PK) (USOTC:MRES)
Historical Stock Chart
From Oct 2024 to Nov 2024
Institute of Biomedical ... (PK) (USOTC:MRES)
Historical Stock Chart
From Nov 2023 to Nov 2024
